Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients

J Infect. 2011 Apr;62(4):319-21. doi: 10.1016/j.jinf.2011.02.004. Epub 2011 Feb 15.
No abstract available

Publication types

  • Case Reports
  • Clinical Trial
  • Letter

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects*
  • Atazanavir Sulfate
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Lamivudine / administration & dosage
  • Male
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects*
  • Organophosphonates / administration & dosage*
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Ritonavir / administration & dosage
  • Tenofovir
  • Urolithiasis / chemically induced*

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Organophosphonates
  • Pyridines
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Atazanavir Sulfate
  • Tenofovir
  • Adenine
  • Ritonavir

Associated data

  • ClinicalTrials.gov/NCT00885482